Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Research & Development (2016 - 2025)

Haemonetics (HAE) has 17 years of Research & Development data on record, last reported at $14.2 million in Q4 2025.

  • For Q4 2025, Research & Development fell 10.37% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $61.2 million, up 1.59%, while the annual FY2025 figure was $62.7 million, 15.22% up from the prior year.
  • Research & Development reached $14.2 million in Q4 2025 per HAE's latest filing, down from $14.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $16.3 million in Q2 2025 and bottomed at $10.0 million in Q1 2022.
  • Average Research & Development over 5 years is $13.4 million, with a median of $13.2 million recorded in 2022.
  • Peak YoY movement for Research & Development: skyrocketed 63.88% in 2021, then decreased 14.16% in 2022.
  • A 5-year view of Research & Development shows it stood at $10.9 million in 2021, then grew by 16.92% to $12.7 million in 2022, then increased by 4.54% to $13.3 million in 2023, then rose by 19.33% to $15.8 million in 2024, then dropped by 10.37% to $14.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $14.2 million in Q4 2025, $14.9 million in Q3 2025, and $16.3 million in Q2 2025.